|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500103396 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-28 16:42:12 |
|
注册时间: Date of Registration: |
2025-05-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
盆底智能诊疗系统在盆腔器官脱垂临床诊治中的真实世界研究 |
|
Public title: |
The real-world study of pelvic intelligence of one solution in the clinical diagonis and treatment of pelvic organ prolapse |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
盆底智能诊疗系统在盆腔器官脱垂临床诊治中的真实世界研究 |
|
Scientific title: |
The real-world study of pelvic intelligence of one solution in the clinical diagonis and treatment of pelvic organ prolapse |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李长忠 |
研究负责人: |
李长忠 |
|
Applicant: |
Li Changzhong |
Study leader: |
Li Changzhong |
|
申请注册联系人电话: Applicant telephone: |
+86 18814351819 |
研究负责人电话:
Study leader's |
+86 15168888909 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lichangzhong@163.com |
研究负责人电子邮件: Study leader's E-mail: |
15168888909@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省深圳市福田区莲花路1120号 |
研究负责人通讯地址: |
广东省深圳市福田区莲花路1120号 |
|
Applicant address: |
No. 1120, Lianhua Road, Futian District, Shenzhen City, Guangdong Province |
Study leader's address: |
No. 1120, Lianhua Road, Futian District, Shenzhen City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京大学深圳医院 |
||
|
Applicant's institution: |
Peking University Shenzhen Hospital |
||
|
研究负责人所在单位: |
北京大学深圳医院 |
||
|
Affiliation of the Leader: |
Peking University Shenzhen Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
北大深医伦审(研)[2025]第(036)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学深圳医院科研伦理审查委员会 |
||
|
Name of the ethic committee: |
Research Ethics Review Committee of Peking University Shenzhen Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-19 00:00:00 | ||
|
伦理委员会联系人: |
陈嘉怡 |
||
|
Contact Name of the ethic committee: |
Chen Jiayi |
||
|
伦理委员会联系地址: |
广东省深圳市福田区莲花路1120号 |
||
|
Contact Address of the ethic committee: |
No. 1120, Lianhua Road, Futian District, Shenzhen City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 83923333 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
jiayichen25@163.com |
|
研究实施负责(组长)单位: |
北京大学深圳医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking University Shenzhen Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省深圳市福田区莲花路1120号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1120, Lianhua Road, Futian District, Shenzhen City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家卫生健康委科学技术研究所 |
||||||||||||||||||||||
|
Source(s) of funding: |
Real-world study on appropriate physical rehabilitation techniques for the whole female reproductive |
||||||||||||||||||||||
|
研究疾病: |
盆腔器官脱垂 |
||||||||||||||||||||||
|
Target disease: |
Pelvic organ prolapse |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究拟观察盆底智能诊疗系统PI-ONE在盆腔器官脱垂诊治中的临床价值及效果,观察并记录治疗中可能存在的不良反应,并探讨临床医师对盆底智能诊疗系统在临床应用中的系统评价,以推动盆底智能诊疗系统在盆底功能障碍性疾病的临床诊治中更广泛的应用。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to observe the clinical value and effect of PI-ONE(pelvic intelligence in one solution) in the diagnosis and treatment of pelvic organ prolapse, observe and record the possible adverse reactions in the treatment, and discuss the systematic evaluation of clinicians on the clinical application of pelvic floor intelligent diagnosis and treatment system, so as to promote the wider application of pelvic floor intelligent diagnosis and treatment system in the clinical diagnosis and treatment of pelvic floor dysfunction diseases. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.根据《盆腔器官脱垂的中国诊治指南》(2020 版)》进行盆腔器官脱垂的诊断; 2.POP-Q 评估 I 度~II 度; 3.年龄 25-55 岁之间; 4.签署知情同意书。本次临床研究,自愿签订知情同意书,并同意按照研究方案的要求参加所有的评估、治疗及随访。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Diagnosis of pelvic organ prolapse according to the Chinese Guidelines for the Diagnosis and Treatment of Pelvic Organ Prolapse (2020 Edition); 2. POP-Q assessment of degree I ~ II degree; 3. Age between 25-55 years; 4. Sign the informed consent form. In this clinical study, voluntarily signed an informed consent form and agreed to participate in all assessments, treatments and follow-up visits as required by the study protocol. |
||||||||||||||||||||||
|
排除标准: |
1.体质指数(BMI)大于等于35; 2.有以下盆腔手术史(子宫切除术、抗尿失禁术、盆底重建术、脱垂修复术等); 3.曾接受过磁电刺激或射频等物理康复治疗; 4.POP-Q评估结果为III度及以上; 5.神经功能障碍、认知障碍、身体活动受限; 6.急性泌尿生殖感染(主要包括急性尿道炎、阴道炎、膀胱炎等); 7.妊娠期、恶露持续期、活动性出血等; 8.盆腔区域有金属植入物; 9.怀疑子宫内膜癌、宫颈癌(可依据3年内体检报告)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Body mass Index (BMI) is greater than or equal to 35; 2.History of pelvic surgery (hysterectomy, anti-incontinence surgery, pelvic floor reconstruction, prolapse repair, etc.); 3.Have received physical rehabilitation treatments such as magnetic and electrical stimulation or radiofrequency; 4.The POP-Q assessment result is grade III or above; 5.Neurological dysfunction, cognitive impairment, and limited physical activity; 6.Acute urogenital infections (mainly including acute urethritis, vaginitis, cystitis, etc.); 7.Pregnancy, lochia persistence period, active bleeding, etc; 8.Metal implants were present in the pelvic region; 9.Suspicion of endometrial cancer and cervical cancer (based on a physical examination report within the past three years). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-09 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-16 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集以病例报告表纸质形式收集,完成后进行电子录入再进行统计分析,原始纸质数据保留在科室档案处或指定位置进行封存5年。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected in paper form on case report forms, entered electronically upon completion and then statistically analyzed, with the original paper data retained in the department archives or designated location for sealing for 10 years. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |